Название продукции:5-chloro-2-(piperidin-4-yl)pyrimidine

IUPAC Name:5-chloro-2-(piperidin-4-yl)pyrimidine

CAS:944903-10-0
Молекулярная формула:C9H12ClN3
Чистота:95%+
Номер в каталоге:CM466825
Молекулярная масса:197.67

Упаковочная единица Доступно для заказа Цена ($) Количество
CM466825-1g 5-6 Weeks ƚȖȯŞ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:944903-10-0
Молекулярная формула:C9H12ClN3
Точка плавления:-
Smiles-код:ClC1=CN=C(N=C1)C1CCNCC1
Плотность:
Номер в каталоге:CM466825
Молекулярная масса:197.67
Точка кипения:
Номер Mdl:MFCD10697164
Хранение:

Category Infos

Piperidines
Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.
Piperidine,Piperidine Price
if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.
Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Nerandomilast
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.